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Abstract
Background Seasonal malaria chemoprevention (SMC)
using sulfadoxine–pyrimethamine plus amodiaquine has
been introduced in 12 African countries. Additional
strategies for safety monitoring are needed to supplement
national systems of spontaneous reporting that are known
to under represent the incidence of adverse reactions.
Objectives This study aimed to determine if adverse event
(AE) reporting could be improved using a smartphone
application provided to village health workers, or by active
follow-up using a symptom card provided to caregivers.
Methods Two strategies to improve reporting of AEs
during SMC campaigns were evaluated, in comparison
with the national system of spontaneous reporting, in 11
health post areas in Senegal. In each health post, an average
of approximately 4000 children under 10 years of age
received SMC treatment each month for 3 months during
the 2015 malaria transmission season—a total of 134,000
treatments. In three health posts (serving approximately
14,000 children), caregivers were encouraged to report any
adverse reactions to the nurse at the health post or to a
community health worker (CHW) in their village, who had
been trained to use a smartphone application to report the
event (enhanced spontaneous reporting). In two health
posts (approximately 10,000 children), active follow-up of
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children at home was organized after each SMC campaign
to ask about AEs that caregivers had been asked to record
on a symptom card (active surveillance). Six health posts
(approximately 23,000 children) followed the national
system of spontaneous reporting using the national
reporting (yellow) form. Each AE report was assessed by a
panel to determine likely association with SMC drugs.
Results The incidence of reported AEs was 2.4, 30.6, and
21.6 per 1000 children treated per month, using the
national system, enhanced spontaneous reporting, and
active surveillance, respectively. The most commonly
reported symptoms were vomiting, fever, and abdominal
pain. The incidence of vomiting, known to be caused by
amodiaquine, was similar using both innovative methods
(10/1000 in the first month, decreasing to 2.5/1000 in the
third month). Despite increased surveillance, no serious
adverse drug reactions were detected.
Conclusion Training CHWs in each village and health facility
staff to report AEs using a mobile phone application led to much
higher reporting rates than through the national system. This
approach is feasible and acceptable, and could be further
improved by strengthening laboratory investigation and the
collection of control data immediately prior to SMC campaigns.
Key Points
Seasonal malaria chemoprevention (SMC) is now
widely used to prevent malaria in children in West
and Central Africa. Good safety monitoring is
essential to ensure SMC programs remain effective.
Training community health workers (CHWs) to
recognize and report adverse events (AEs) improved
detection of adverse drug reactions in this study
in Southern Senegal.
Training CHWs and health facility staff to report
using a mobile phone application enhanced safety
reporting and improved timeliness of notifications
during SMC campaigns.
No serious AEs were detected despite enhanced
surveillance.
1 Introduction
Malaria remains a major public health concern in the
world, particularly in sub-Saharan Africa. The World
Health Organization (WHO) estimates 216 million malaria
cases and 445,000 malaria deaths occurred in 2016 [1],
with the vast majority of malaria deaths occurring in
children in sub-Saharan Africa caused by Plasmodium
falciparum. Since 2012, the WHO has recommended sea-
sonal malaria chemoprevention (SMC), consisting of the
monthly administration of a full course of treatment with
sulfadoxine–pyrimethamine (SP) and amodiaquine (AQ),
during the transmission season to prevent malaria.
Although SMC is recommended for children aged
3–59 months [2], in Senegal (as in many other areas where
SMC is used) there is a substantial burden of severe
malaria illness in older children. The Senegalese Ministry
of Health made the decision to provide SMC for children
up to 10 years of age when SMC was first introduced. After
a pilot implementation in 2013, SMC was implemented in
four regions of the country where malaria transmission was
most intense (Kedougou, Kolda, Tambacounda and Sed-
hiou), in a population of approximately 600,000 children.
From 2013 to 2017, approximately 8 million treatments
were administered. A total of seven serious adverse events
(SAEs) related to SMC have been reported in Senegal since
the introduction of SMC, up to 2017: a case of Stevens–
Johnson syndrome and a case of toxic epidermal necroly-
sis, both in 2014; a case of extrapyramidal syndrome and
two cases of anaphylactic reactions in 2015; and one case
of Stevens–Johnson syndrome and one anaphylactic reac-
tion in 2016. No SAEs were reported in 2017. Although
pharmacovigilance during SMC campaigns was strength-
ened through training of health staff to recognize adverse
reactions to SMC drugs, there is concern that adverse
events (AEs) are being underreported. Known adverse
reactions to SP and AQ have been reviewed by Phillips-
Howard and Bjorkman [3] and, more recently, NDiaye
et al. [4]. AQ is associated with vomiting, extrapyramidal
reactions, liver toxicity, and agranulocytosis, while SP can
cause liver toxicity and severe cutaneous reactions,
including Stevens–Johnson syndrome and toxic epidermal
necrolysis, which are rare but life-threatening medical
emergencies.
Pharmacovigilance systems based on spontaneous
reporting are relatively simple and inexpensive to establish
but often suffer from poor quality of reporting, as well as
underreporting [5]. In addition, it is difficult to estimate
incidence rates of AEs through a spontaneous reporting
system, generally because of lack of a denominator
(number of people exposed). Additional methods are nee-
ded to determine the safety profile of new medicines, as
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well as medicines put to new uses, in public health pro-
grams [6]. This is especially important in the framework of
mass administration of preventive treatment to children,
delivered by community workers with limited medical
training. SAEs to SMC drugs appear to be uncommon, but,
especially in the initial phases of SMC programs, there is a
need to supplement the national system of spontaneous
reporting with additional methods of surveillance.
The aim of this study was to evaluate whether AE
reporting could be improved using one of two approaches:
(1) reporting using a smartphone application when patients
presented at the clinic or to a village health worker; and (2)
active follow-up of children at home to ask about AEs and
collect information caregivers were asked to record on a
symptom card, compared with the current national system
for spontaneous reporting alone. Feasibility and accept-
ability of the implementation of the strategies were also
assessed.
2 Methods
2.1 Study Population
This study was conducted in the health districts of Kolda
and Sedhiou in the south of Senegal (Electronic Supple-
mentary Fig. S1) during the SMC campaign of 2015 (Au-
gust, September, and October). The population is primarily
rural. In 2016, the under-5 mortality rate was estimated to
be 100 per 1000 children, and the literacy rate was 55% in
men and 41% in women [7].
Malaria is a major cause of severe illness in children.
Community case management for malaria is provided in
the more remote villages by a community health worker
(Distributeur de Soins a` Domicile [DSDOM]) working
from their home or at a case de sante´ (health hut). SMC
targeted children aged 3 months to 10 years and is deliv-
ered door-to-door by the DSDOM and (in villages that do
not have a resident health worker) by relais communau-
taires (community volunteers). In this report, DSDOM and
relais communautaires are collectively referred to as
community health workers (CHWs). SMC delivery is
coordinated by the health post from where CHWs collect
drugs each day, with SMC distribution following general
WHO recommendations [8]. One dose of SP and the first
dose of AQ were administered by the CHW on the first day,
and the remaining two doses of AQ were left with the
caregiver to administer over the next days. Children who
are unwell are referred without treatment, however they
may then receive SMC at the health post. CHWs are
trained to exclude children with a history of allergy to SMC
drugs and any child who had received SP, AQ, or a sulfa-
containing antibiotic in the previous month. Treatments
administered are recorded on tally sheets that are collated
to give monthly totals.
2.2 Study Design
Eleven health posts in SMC implementation areas were
selected and assigned to monitor SMC safety using one of
three methods: safety monitoring employing the national
system of spontaneous reporting using the national
reporting form (referred to as the national system), com-
pleted by nurses or physicians at health facilities; reporting
using mobile phones (enhanced spontaneous reporting),
completed by nurses at health posts and by CHWs; and
active follow-up of children at home after each SMC
campaign to ask about AEs and collect information that
caregivers had been asked to record on a symptom card
(active surveillance). Enhanced spontaneous reporting with
mobile phones was implemented in two health posts in
Kolda, and active surveillance was implemented in three
health posts in Sedhiou. For comparison, three health posts
in each district, where the staff were trained to report
events using the national reporting form, acted as controls.
2.3 Sample Size, Allocation, and Description
of Surveillance Methods
In each district, two groups of health posts were selected,
with a total of approximately 10,000 children per group.
The two groups were then randomly allocated within each
district to either control or enhanced or active surveillance.
The sample size of 10,000 children permits event rates
above 0.3/1000 children to be ruled out if zero events are
observed, and is sufficient to give 99% probability of
detecting at least one event if the rate is 1/2000 or more. As
SMC was administered to each child up to three times, the
power for detecting events per 1000 treatments is greater.
Two health posts in Sedhiou (Diende´ and Dembo Coly,
including 53 villages) were assigned to enhanced sponta-
neous reporting, and three health posts in Kolda (Ba-
gadadji, Dabo and Sikilo Ouest, including 106 villages)
were assigned to active surveillance. Six health posts, three
in each district, assigned to the national system, acted as
controls (Table 1). In the area assigned to active surveil-
lance, consent to participate in the study was sought when
CHWs visited to administer the first monthly SMC
treatment.
2.4 Enhanced Spontaneous Reporting
At the time of each monthly SMC distribution, caregivers
were encouraged to contact the nearest CHW (DSDOM) or
the health post if the child was unwell after SMC admin-
istration. The nurses and the CHWs first entered the patient
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details in the consultation register and treated or referred
the patient as appropriate. Then, in the case of children
over 3 months and under 10 years of age who had received
SMC and had any illness, the nurses and CHWs entered the
name, age and sex of the child, all medicines received in
the last month and the date of administration, and the date
of onset of symptoms and a description of the symptoms,
into a smartphone application which then uploaded the data
over the internet to a server in the project office in Dakar.
The application was designed using Survey CTO (Dobility,
Inc., Wilmington, DE, USA), a platform based on Open
Data Kit (ODK), an open source set of programming tools
for data capture. The date of the report was generated
automatically. The phones were Samsung Duo, costing
CFA 30,000 each (US $51 at 2015 exchange rates), pro-
vided with SIM cards and internet credit to cover the costs
of data uploading. The project team sent an SMS to each
health worker each day to feed back to them the number of
reports received from them the previous day and the total
number from the start of the study. The team contacted
health workers who had not submitted any report the pre-
vious day to confirm there were no events. A database of
all events reported was updated daily and shared with the
project team. If the nurse suspected the illness was an
adverse drug reaction (ADR), a national reporting form
(yellow form) was completed.
2.5 Active Surveillance
At the time of each monthly SMC administration, CHWs
delivering SMC gave caregivers a card for each child,
which showed images illustrating fever, vomiting, rash,
and pain. The caregiver was asked to tick the card if the
child had one of these symptoms or any other symptoms at
any time after SMC administration. The same CHWs went
back to each household after the end of each monthly
campaign, between 6 and 12 days after the first day of the
SMC cycle, to ask caregivers about any AEs in children
who had received SMC. CHWs asked about additional
details, the date symptoms started, and, if the child no
longer had symptoms, the date symptoms stopped, which
the CHW then recorded on the card. The cards were col-
lected and taken to the health post, where the nurse
reviewed them before entering the information into a
Microsoft Excel database. If the child was still unwell
when the CHW visited, the child was referred to the nurse
at the health post, who completed a national reporting
(yellow) form.
2.6 National System
The nurse at each health post was trained to complete a
national reporting form (yellow form) for any child
Table 1 Number of staff trained for pharmacovigilance in each health facility, size of the catchment population, number of children eligible for
SMC, and number of children who received SMC treatment each month
District Health post Method used for
PV
No. of health staff trained for
PV: nurses (CHWs)
Total
population in
2015
SMC target
population
No. of children who received
SMC treatment
September October November
Sedhiou Diende Enhanced
spontaneous
reporting
1 (9) 21,958 6587 4787 4849 5134
Dembo
Coly
Enhanced
spontaneous
reporting
1 (9) 25,486 7646 7545 7574 7569
Djibabouya National system 1 (10) 12,228 3668 2862 3008 3067
Bambaly National system 1 (10) 17,162 5148 3851 4100 4509
Djiredji National system 1 (10) 11,337 3401 3956 4004 3976
Kolda Bagadadji Active
surveillance
1 (6) 14,862 4459 4393 4454 4576
Dabo Active
surveillance
1 (6) 9705 2911 3057 3058 3065
Sikilo
Ouest
Active
surveillance
1 (10) 8011 2403 2732 2994 3123
Sikolo Est National system 1 (10) 9412 2824 2794 2654 2675
Dioulacolon National system 1 (10) 16,619 4986 4997 4974 5121
Guiro Yero
Boucar
National system 1 (10) 9560 2868 2824 2925 2854
PV pharmacovigilance, CHWs community health workers, SMC seasonal malaria chemoprevention
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presenting to the health post with suspected AEs, as per the
national pharmacovigilance guidelines [6]. During SMC
campaigns, yellow forms from all health posts were col-
lected at the district health center. District teams could then
enter the forms into a Microsoft Excel database that was
forwarded to the regional health team, or the forms were
sent to the regional team where they were entered. A final
database was then sent to the Centre Anti-poison and the
National Malaria Control Programme each month.
2.7 Training
An information sheet describing the symptoms of the
known AEs and highlighting vomiting, skin rash, and signs
of jaundice was prepared and used to train health staff. In
all health posts, training for SMC delivery included health
facility staff and CHWs, and covered key messages about
pharmacovigilance, the symptoms of the known ADRs to
SMC drugs, and how to report events using the national
form. In addition, for staff in health posts using the
smartphones, training was held in each district over 2 days
to explain how to report using the smartphone application.
Training included practical sessions on AE reporting, and
emphasized the importance of checking information before
uploading, and the responsibilities of the nurses and CHWs
in pharmacovigilance.
2.8 Sensitization and Study Preparation
Meetings were held with regional and district medical
officers to emphasize the importance of ensuring that lab-
oratories had reagents for liver function tests and hema-
tology. In each district, a hospital pharmacist was
nominated to be the pharmacovigilance coordinator, and a
study project manager was appointed. In all health posts,
communities were informed about the SMC campaign,
including reminders to bring the child to a health worker if
the child was sick after taking SMC medicine. In addition,
in health posts with enhanced passive or active surveil-
lance, additional community sensitization was organized
by the health post nurse.
2.9 Data Management and Statistical Analysis
Incidence rates were calculated per 1000 child months,
using the estimated number of children who received SMC
each month as the denominator. Rate ratios were used to
compare rates between surveillance methods, age groups,
and calendar months, estimated using Poisson regression
with a robust standard error to account for clustering within
health posts and with stratification by district. The mean
number of symptoms reported per patient was compared
with Poisson regression. To assess whether particular
symptoms tended to be reported together, odds ratios for
associations between symptom pairs were compared
between groups, using a test of homogeneity, for the four
most commonly reported symptoms. Data were analyzed
using Stata 13 (StataCorp LLC, College Station, TX,
USA).
2.10 Causality Assessment
Health workers were asked to report any illness as AEs not
necessarily having a causal relationship with medical
treatment. The Centre Antipoison of Senegal and the
pharmacovigilance Technical Committee analyzed the
reports and assessed the severity and association with
medicine intake following the WHO method [9]. All case
reports were submitted to the international drug monitoring
database through Vigiflow.
2.11 Ethics
The research protocol and documents given to participants
were submitted to the National Ethics Committee of
Senegal and approval obtained prior to the start of the
study. Administrative authorization was also given by the
Ministry of Health. Community consent was obtained for
the phone-reporting pharmacovigilance prior to the begin-
ning of the study. For children in the active surveillance
group, signed consent was sought from a parent or guardian
after explaining the aims and procedures involved. An
advisory committee was set up by the National Malaria
Control Programme at central level to provide guidance on
the management of any severe AEs during SMC
campaigns.
3 Results
A total of 1983 AEs were reported over the 3 months of
surveillance, out of a total of 134,061 monthly treatments.
Of these, 158 were reported through the national system (a
rate of 2.4/1000 children treated/month), 1145 (31/1000
children/month) were reported through the enhanced
spontaneous reporting system using CHWs and mobile
phones, and 680 (22/1000 children/month) were reported
through active surveillance. All patients reported having
taken SMC drugs, and 154/1983 (7.8%) had taken one or
more other medications in addition to SMC drugs, com-
prising 53 who had taken camphorated tincture of opium
(paregoric, a diarrhea treatment including 0.4 mg/mL
morphine), 49 who had taken metopimazine (an antie-
metic), 43 who had taken paracetamol, 24 who had taken
zinc, 7 who had taken phloroglucinol (a treatment for
abdominal pain), 2 who had taken amoxicillin, 2 who had
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taken mequitazine (an antihistamine), 2 who had taken
metronidazole (an antibiotic used to treat protozoal infec-
tion), 1 who had taken chloroquine, and 1 who had taken
traditional medicine. None of the events reported were
considered serious.
3.1 Enhanced Spontaneous Reporting
Overall, 1145 events were reported over 3 months, a rate of
30.6 [95% confidence interval (CI) 28.8–32.4] per 1000
children treated per month, compared with a rate of 1.65
(95% CI 1.27–2.15) per 1000 per month in health posts
using the national system (Table 2). A total of 927 events
(81% of the total) occurred within 10 days of the start of
the SMC cycle. The incidence of AEs decreased in each
successive month, from 30.1/1000 in September, to 25.2 in
October and 10.1 in November. The incidence was slightly
lower in infants than in older children (Table 4). The most
commonly reported symptoms were fever, vomiting, and
abdominal pain (Fig. 1). Among the older children
(5–10 years of age), the most common symptoms were, in
descending order, fever, vomiting, abdominal pain, head-
ache, and diarrhea (Fig. 2), with a similar pattern being
observed in the 12–59 months age group. Among children
aged 3–11 months, the most common symptoms were
fever and diarrhea. Tiredness, cough, loss of appetite,
dizziness, and pruritus were less commonly reported, and
other symptoms (Electronic Supplementary Table S4)
together accounted for\ 1% of reported symptoms. No
AE was considered serious. The average number of
symptoms reported per event was 1.67, with 50% of
patients reporting more than one symptom. The distribution
of the number of symptoms per event is shown in elec-
tronic supplementary Table S2. Symptoms varied by age
group (Fig. 2). Vomiting was reported at a rate of 10.7/
1000/month (Table 3), and was most commonly associated
with diarrhea or fever (electronic supplementary Table S3).
When the reports were assessed for their relationship with
SMC drugs, 27% of AEs were considered probably related
to SMC, 36% were possibly related, 1.2% were unlikely to
be related, and causality could not be assessed for the
remaining 36%.
In health posts in the same district that used the national
system of reporting, there were 55 events, a rate of 1.65/
1000/month. Rates similarly declined with each successive
month. No AE was considered serious. When reports were
assessed for their association with SMC drugs, 11% were
considered probably related to SMC, 81% possibly related,
1.2% unlikely to be related, and 6.3% could not be
classified.
Enhanced reporting involving CHWs and using mobile
phones increased reporting 18-fold (rate ratio 18.5, 95% CI
8.65–39.7), and the incidence of episodes of vomiting by
10-fold (rate ratio 10.2, 95% CI 5.8–18.0).
3.2 Active Surveillance
Overall, 680 events were reported over 3 months, corre-
sponding to a rate of 21.6 (95% CI 20.1–23.3) per 1000
children treated per month, compared with a rate of 3.24
Table 2 Incidence of adverse events (reports with one or more symptoms) following SMC distribution, using three methods of surveillance
No. of events No. of treatments Incidence rate/1000 (95% CI) Incidence rate ratio (95% CI)a
Kolda
National system 103 31,818 3.2 (2.7–3.9) Reference
Active surveillance 680 31,452 21.6 (20.1–23.3) 6.7 (1.3–33.9)
Sedhiou
National system 55 33,333 1.65 (1.3–2.1) Reference
Enhanced spontaneous reporting 1145 37,458 30.6 (28.8–32.4) 18.5 (8.65–39.7)
SMC seasonal malaria chemoprevention, CI confidence interval
aIncidence rate ratios comparing the surveillance methods were estimated using Poisson regression, with the estimated number of SMC
treatments as offset, and using robust standard errors to account for clustering within health post
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Fig. 1 Average incidence of each symptom, as reported through each
method of surveillance
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(95% CI 2.67–3.93) per 1000 per month in health posts
using the national system. The incidence of AEs decreased
in each successive month, from 30.1/1000 in September, to
25.2 in October and 10.1 in November. The incidence rate
increased with increasing age, from 12.1/1000/month in
infants, to 21.5 in children 12–59 months of age, and 24.0
in older children (Tables 4 and 5). The average number of
symptoms reported per event was 1.2, with only one
symptom reported in the majority (79%) of events. Among
the older children (5–10 years of age), the most common
symptoms were, in descending order, vomiting, abdominal
pain, fever, diarrhea, and headache. Vomiting was reported
at a rate of 10.7/1000/month. Other symptoms included
itching, lethargy, cough, loss of appetite, and dizziness, but
these were uncommon. No AE was considered serious.
When reports were assessed for their association with SMC
drugs, 8.6% were considered probably related to SMC,
72% possibly related, 0.24% were unlikely, and 19% could
not be classified.
In health posts in the same district which used the
national system of reporting, 103 events (3.24/1000/month)
were reported. No AE was considered serious. Twenty
percent of these reports were considered probably related
to SMC, 70% were possibly related, while the remaining
10% could not be classified. Active surveillance increased
reporting almost sevenfold (rate ratio 6.7, 95% CI
1.3–33.9) and reporting of episodes of vomiting by sev-
enfold (rate ratio 7.2, 95% CI 1.8–29.1).
4 Discussion
Although efforts have been made to strengthen national
pharmacovigilance capacity during SMC programs [10], it
is recognized that national systems based on spontaneous
reporting tend to underreport events. There might be
multiple reasons for this: (1) events may not be recognized
by the health worker as potentially related to administration
of the medicine; (2) health staff may be too busy to report
the event, or may not know how to report; or (3) the patient
may seek care outside the formal health system. Mild and
moderate events may be particularly underrepresented as
events may not be considered severe enough by a patient to
warrant consulting a health worker, or not considered by
Fig. 2 Incidence of adverse events, by age group, for each surveillance method. a Enhanced spontaneous reporting; b active surveillance
Table 3 Incidence of vomiting following SMC distribution, using three methods of surveillance
No. of events No. of treatments Incidence rate/1000 (95% CI) Incidence
rate ratio (95% CI)
Kolda
National system 47 31,818 1.5 (1.1–2.0) Reference
Active surveillance 335 31,452 10.7 (9.6–11.9) 7.2 (1.8–29.1)
Sedhiou
National system 34 33,333 1.0 (0.73–1.4) Reference
Enhanced spontaneous reporting 389 37,458 10.4 (9.4–11.5) 10.2 (5.8–18.0)
SMC seasonal malaria chemoprevention, CI confidence interval
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health workers to be important enough to report, but these
could become a concern (jeopardizing acceptability or
adherence to treatment) if common. A further problem is
that reports are slow to reach national pharmacovigilance
and malaria program coordinators, therefore investigation
(and the putting in place of any mitigating actions) may be
considerably delayed. More intensive monitoring is there-
fore required, especially in the early phases of a new public
health program, to establish its safety [6].
In October 2014, a workshop was organized by the
Special Programme for Research and Training in Tropical
Diseases (TDR) and the London School of Hygiene &
Table 4 Incidence of adverse
events (reports with one or more
symptoms) following SMC
distribution, using three
methods of surveillance, by age
group and month of
administration
No. of
events
No. of treatments Incidence/1000 Incidence rate ratio (95% CI)
Kolda
Active surveillance
Age group (months)
3–11 39 3212 12.1 0.56 (0.44–0.70)
12–59 324 15,052 21.5 Reference
60–120 317 13,188 24.0 1.12 (1.10–1.15)
Month
September 306 10,182 30.1 Reference
October 265 10,506 25.2 0.84 (0.35–2.03)
November 109 10,764 10.1 0.33 (0.09–1.26)
Kolda
National system
Age group (months)
3–11 4 2842 1.4 0.45 (0.32–0.62)
12–59 48 15,255 3.1 Reference
60–120 51 13,721 3.7 1.16 (0.60–2.24)
Month
September 77 10,615 7.3 Reference
October 19 10,553 1.8 0.25 (0.09–0.68)
November 7 10,650 0.7 0.09 (0.03–0.25)
Sedhiou
Enhanced spontaneous reporting
Age group (months)
3–11 114 3491 32.7 1.00 (0.73–1.38)
12–59 557 17,142 32.5 Reference
60–120 474 16,825 28.2 0.85 (0.77–0.94)
Month
September 570 12,332 46.2 Reference
October 406 12,423 32.7 0.71 (0.38–1.30)
November 169 12,703 13.3 0.29 (0.24–0.35)
Sedhiou
National system
Age group (months)
3–11 8 2331 3.4 2.57 (1.89–3.48)
12–59 22 16,170 1.4 Reference
60–120 25 14,832 1.7 1.21 (0.46–3.19)
Month
September 31 10,669 2.9 Reference
October 11 11,112 1.0 0.34 (0.24–0.48)
November 13 11,552 1.1 0.38 (0.24–0.62)
SMC seasonal malaria chemoprevention, CI confidence interval
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Tropical Medicine (LSHTM) to bring together coordinators
of national malaria control programs and national phar-
macovigilance centers from countries that had introduced
SMC, or planned to in the near future, to discuss with
pharmacovigilance experts approaches that could be used
to improve safety monitoring of SMC programs. The
workshop highlighted the need for operational research
into innovative practical methods that could simplify and
expedite reporting and improve promptness of notification
of events to the national malaria program and the phar-
macovigilance center [11]. This led to planning of the
present study that evaluated two approaches to community-
Table 5 Incidence of vomiting
following SMC distribution,
using three methods of
surveillance, by age group and
month of administration
No. of events No. of treatments Rate/1000 (95% CI) Rate ratio (95% CI)
Kolda
Active surveillance
Age group (months)
3–11 15 3212 4.67 (2.82–7.75) 0.47 (0.23–0.95)
12–59 147 15,052 9.77 (8.31–11.48) Reference
60–120 173 13,188 13.12 (11.30–15.23) 1.36 (1.10–1.67)
Month
September 171 10,182 16.79 (14.46–19.51) Reference
October 117 10,506 11.14 (9.29–13.35) 0.66 (0.32–1.37)
November 47 10,764 4.37 (3.28–5.81) 0.26 (0.07–0.99)
Kolda
National system
Age group (months)
3–11 1 2842 0.35 (0.05–2.5) 0.28 (0.02,3.31)
12–59 19 15,255 1.2 (0.79–1.95) Reference
60–120 27 13,721 2.0 (1.3–2.9) 1.54 (0.51–4.66)
Month
September 41 10,615 3.9 (2.8–5.2) Reference
October 5 10,553 0.47 (0.20–1.14) 0.12 (0.02–0.68)
November 1 10,650 0.09 (0.01–0.67) 0.02 (0.00–0.13)
Sedhiou
Enhanced spontaneous reporting
Age group (months)
3–11 15 3491 4.30 (2.59–7.13) 0.39 (0.21–0.70)
12–59 189 17,142 11.03 (9.56–12.72) Reference
60–120 185 16,825 11.00 (9.52–12.70) 0.98 (0.98–0.98)
Month
September 207 12,332 16.79 (14.65–19.24) Reference
October 123 12,423 9.90 (8.30–11.82) 0.59 (0.42–0.82)
November 59 12,703 4.65 (3.60–6.00) 0.28 (0.26–0.29)
Sedhiou
National system
Age group (months)
3–11 4 2331 1.72 (0.64–4.57) 2.82 (1.10–7.28)
12–59 10 16,170 0.62 (0.33–1.15) Reference
60–120 20 14,832 1.35 (0.87–2.09) 2.13 (0.89–5.10)
Month
September 20 10,669 1.88 (1.21–2.91) Reference
October 6 11,112 0.54 (0.24–1.20) 0.29 (0.11–0.77)
November 8 11,552 0.69 (0.35–1.39) 0.37 (0.15–0.94)
SMC seasonal malaria chemoprevention, CI confidence interval
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based pharmacovigilance involving CHWs; one based on
passive, spontaneous reporting in which CHWs and health
facility staff were trained to report AEs using a mobile
phone application, and the other approach involving active
follow-up by CHWs after each SMC campaign to ask about
AEs that caregivers had been asked to record on a symptom
card. Both methods involved sensitization of the commu-
nity to the importance of reporting suspected AEs, and a
central supervision team to process, share, and analyze
reports and to provide feedback to reporters.
The incidence rate of reported events was higher using
community-based spontaneous reporting—31/1000 chil-
dren/month, compared with 22/1000 children/month using
active surveillance. These rates compare with rates of
1.7–3.2 through the national system in the same districts.
The greater incidence in the enhanced spontaneous
reporting arm of the study reflects the longer period of time
over which events were observed. In the active surveillance
arm of the study, participants were asked about events
occurring up to 10 days prior to the visit, whereas any
event during the month could be reported in the enhanced
spontaneous reporting arm.
When specific symptoms were considered, the incidence
rate of vomiting, which, it is known, can be caused by AQ,
was seen to be similar in the active and enhanced sponta-
neous reporting arms of the study in infants and young
children, and slightly more common among older children
in the active arm of the study, while fever and diarrhea
were more commonly reported in the spontaneous report-
ing arm of the study. It was hypothesized before the study
that mild side effects would not be reported spontaneously
and active surveillance would be necessary to determine
the true burden. The fact that the incidence of vomiting was
similar using both methods suggests this is not the case
when good access is provided through CHWs based in the
village. In the enhanced spontaneous reporting arm of the
study, 16 CHWs were based in the community, to whom
patients could report, in addition to the two health post
nurses. It is likely that this improved access for patients,
and the provision of training for these staff to recognize
AEs and when and how to report, may have contributed to
the high reporting rate, as has been found in other studies
[12].
None of the reported AEs was classified as serious. As
the number of children who received SMC in the intensi-
fied surveillance area was at least 23,000, the upper 95%
confidence limit for the rate of severe AEs per child was 1
in 7800 (i.e. on the basis of this study we can rule out rates
greater than this).
A limitation of this study is the lack of suitable controls
to establish the rate of symptoms in children who did not
receive SMC. Data could have been collected prior to the
start of the SMC campaigns, although some confounding
would remain, as, in this population, morbidity is seasonal,
with the rainy season being associated with the transmis-
sion of infections and with malnutrition. In this study, in
the enhanced and active surveillance areas, health workers
were encouraged to report all events. When reports were
assessed for evidence of a relationship with SMC drugs,
over one-third could not be reliably classified. Therefore,
the overall rates are likely to overestimate the true rates of
AEs to SMC drugs, but the rates (or rather the upper
confidence limits on the rates) can be interpreted as rep-
resenting an upper bound for the true rate of drug-related
symptoms. Furthermore, there may have been reporting
bias, both by caregivers who may have been less likely to
report symptoms not listed on the symptom card, and by
CHWs, whose training emphasized the known side effects
of SMC drugs. A further limitation of the study (in com-
mon with routine pharmacovigilance) is that although steps
were taken to improve laboratory capacity for routine
investigation, it was not possible to routinely perform
hematological analysis or liver function tests, and therefore
it is possible that cases of clinically silent neutropenia
(which can be associated with AQ) and hepatitis (which
can be associated with both AQ and SP) may have gone
undetected. Severe cutaneous reactions, known to be
associated with SP, and extrapyramidal syndrome, known
to be caused by AQ, are severe and unmistakable, and the
fact that no cases of these syndromes were seen suggests it
is unlikely that any such events occurred during the study
period in the populations under enhanced or active
surveillance.
The most commonly reported symptoms were gas-
trointestinal disorders (nausea/vomiting, abdominal pain,
diarrhea), fever, headache, tiredness, cough, loss of appe-
tite, dizziness and pruritus. These symptoms were similar
to those reported in other studies of antimalarials in chil-
dren in the Central African Republic [13], Burkina Faso
[14], and Senegal [4], and in school children in Uganda
[15]. Fever was more commonly reported in our study
compared with other studies on SP ? AQ, but this may
reflect that the definition of fever includes a reported his-
tory of fever, and that the study took place over an
extended period during the rainy season, when febrile ill-
nesses are common.
The incidence of AEs decreased in successive rounds of
SMC, a finding that is consistent with the results of others
studies [4, 14]. The fact that this effect was observed in
active and passive surveillance areas suggests there may
have been gradual tolerization to the effects of AQ;
mothers could also become less likely to report mild
symptoms over time.
For reports submitted by mobile phone, the average delay
from case presentation to the notification reaching the cen-
tral office was 24 h. In a study using SMS to monitor AEs
198 J. A. Ndiaye et al.
after immunization in Australia, most patients who received
an SMS query about adverse vaccine reactions sent a
response within 2 h of receiving the query [16]. A study in
Ghana, where the use of mobile phones to contact patients
was compared with home visits to identify AEs related to
artemisinin-based combination therapy for treating uncom-
plicated malaria found a slightly higher reporting rate with
mobile phones, and that it was possible to interview the
majority of patients within a few days [17]. In Uganda, an
SMS-based reporting system for monitoring malaria diag-
nosis and treatment improved timeliness in data reporting
[18]. A pilot study in rural districts of Kenya using mobile
text messaging for malaria surveillance demonstrated that
phone reporting can improve timeliness and reporting of
data [19]. Semi-structured interviews and focus group dis-
cussions conducted in conjunction with this study indicated
that active surveillance was appreciated by community
members, but CHWs found this time-consuming and con-
sidered enhanced spontaneous reporting to be effective;
however, technical difficulties in terms of electricity supply
and internet connections were noted. The authors intend to
publish results from this aspect of the study separately.
5 Conclusions
This study has shown that involving CHWs in safety
reporting, and training nurses and CHWs to report using a
mobile phone application, can be used to enhance safety
reporting and improve timeliness of notifications, but the
approach relies on training and supervision of CHWs and
health facility staff, effective community sensitization, and
a central team to process reports and provide feedback.
These strategies could be adopted in sentinel sites when
new public health programs are introduced and scaled up.
Enhanced safety monitoring using this approach could be
established in SMC areas; however, for comparison, lab-
oratory investigation should be strengthened and baseline
incidence should be collected prior to SMC campaigns.
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